CSTL (Castle Biosciences) ROCE %: -11.32% (As of Mar. 2026)


CSTL Castle Biosciences Inc CSTL
72 GF Score
Price $22.29
GF Value $29.15
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Castle Biosciences ROCE %?

Castle Biosciences CSTL +0.77% 72 ROCE % is -11.32% as of Mar. 2026. GuruFocus rates CSTL with a GF Score™ of 72/100 and a GF Value™ of $29.15 (Modestly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Castle Biosciences's annualized ROCE % for the quarter that ended in Mar. 2026 was -11.32%.

Castle Biosciences  (NAS:CSTL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Castle Biosciences ROCE % Related Terms

Castle Biosciences ROCE % Historical Data

* Premium members only.

The historical data trend for Castle Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Castle Biosciences ROCE % Chart

Castle Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -9.35 -16.23 -14.04 4.99 -5.93

Castle Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.20 -0.10 -0.29 -2.12 -11.32
CSTL
72GF Score
Castle Biosciences Inc CSTL
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Castle Biosciences ROCE % Calculation

Castle Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-29.428/( ( (531.235 - 49.392) + (578.556 - 68.677) )/ 2 )
=-29.428/( (481.843+509.879)/ 2 )
=-29.428/495.861
=-5.93 %

Castle Biosciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-57.116/( ( (578.556 - 68.677) + (547.805 - 48.761) )/ 2 )
=-57.116/( ( 509.879 + 499.044 )/ 2 )
=-57.116/504.4615
=-11.32 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -11.32% mean?
Castle Biosciences (CSTL) has a ROCE % of -11.32% as of Mar. 2026.
Is Castle Biosciences' ROCE % too high?
Castle Biosciences' current ROCE % is -11.32%. Overall, Castle Biosciences has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' ROCE % compare to FLGT and MYGN?
Castle Biosciences' ROCE % of -11.32% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Castle Biosciences's current ROCE % is -11.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.15, compared to a current price of $22.29 — trading 23.5% below its estimated fair value. The current ROCE % is -11.32%. Castle Biosciences' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current ROCE % is -11.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Castle Biosciences (CSTL) Overvalued in 2026?

Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued. The current stock price of $22.29 is trading 23.5% below its estimated GF Value™ of $29.15. GuruFocus considers Castle Biosciences to be Modestly Undervalued.

Key valuation signals for CSTL:

  • ROCE %: -11.32%
  • GF Value™: $29.15 vs. price of $22.29 (23.5% below fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Castle Biosciences Business Description

Other Exchanges 086:Germany
Address 1500 West Parkwood Avenue, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
72GF Score

Get the complete analysis for CSTL

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.29
Price
$29.15
GF Value